Abstract: AIM: To compare the therapy of the combination of benazepril and levamlodipine (B/LA) with benazepriland and nifedepine sustained-release tablet (B/NSr) in patients with mild to moderate hypertension inadequately controlled by benazepril alone.METHODS: Experiments were performed in 112 patients with primary hypertension inadequately controlled by benazepril alone. The patients were randomized divided into two groups. Continued previous benazepril treatment, the B/LA group (n =56) was added levamlodipine, 2.5 mg once daily for 2 weeks, the B/NSr group (n =56) was added nifedepine sustained-release tablets, 10 mg once daily for 2 weeks.Examinations were performed before and at the end of 2 weeks of combination-treatment period.The total combination-treatment period was 4-6 weeks.RESULTS: The overall Bp-reducing efficacious rate of LA/B group was 85.71 %, and that of LA/B group was 78.57 % (P >0.05), but the obvious Bp-reducing rate in B/LA group was 73.21 %, which was significantly higher than that in B/NSr group (57.14 %, P <0.05). The adverse effects rate was 8.93 % in B/LA group and 21.43 % in B/NSr group (P <0.01).CONCLUSION: Either LA/B or B/NSr is effective in the treatment of hypertension inadequately controlled by benazepril alone, but LA/B is more desirable therapy than B/NSr.

Key words: primary hypertension, benazepril, Levamlodipine, nifedepine sustained-release tablet